China Resources Sanjiu revamps governance, forecasts substantial 2026 related-party transactions

China Resources Sanjiu Medical & Pharmaceutical has approved comprehensive revisions to its Articles of Association, effective December 9, 2025. These amendments streamline corporate governance by eliminating the Board of Supervisors, transferring its duties to the Board's Audit Committee, and adjusting the company's total share capital to 1,664,217,858 shares and its registered capital to RMB 1,664,217,858 following 2024 profit distribution and restricted stock repurchases. The revisions also clarify internal management structures and enhance disclosure requirements for various financial activities.

Concurrently, the company has updated its External Guarantee Management System, Cash Management System, Information Disclosure Management System, and other related policies to strengthen risk control and ensure compliance. Furthermore, China Resources Sanjiu forecasts 2026 related-party transactions totaling no more than RMB 494,427.53m, with sales to related parties expected at RMB 446,292.11m and purchases from related parties at RMB 48,135.42m. These transactions are primarily with entities controlled by China Resources Co., Ltd. and aim to maintain stable operations, with pricing based on market rates.

The company also secured approval for a total bank credit line of RMB 95bn with eight banks to meet financing needs and reduce costs, with the credit facilities valid for 12 months. This, along with revisions to its internal audit and information disclosure frameworks, underscores China Resources Sanjiu’s commitment to robust financial management and transparency.